Additional information
Manufacturer |
GRACE |
---|---|
Quality |
JPE, USP-NF |
Cas-No |
7631-86-9 |
Einecs |
231-545-4 |
Composition |
mesoporous silica gel |
Dosage Form |
OSD |
Function |
DC Excipient, Drug Carrier |
€0.00
Amorphisation of crystalline APIs for better bioavailability/solubility.
Our SILSOL® silica active ingredient delivery technology combines Grace’s extensive expertise in mesoporous silica gel, novel application methods, and patented technologies to accelerate the screening and development of solubility enhancing solid dispersions, with the added benefit of doing so with compendial, scalable, and available silicas.
Grace’s SILSOL® silica active ingredient delivery technology offers several critical benefits:
Compared to other bioavailability enhancing techniques such as particle size reduction, complexation, lipid-based systems, and polymer-based solid dispersions, our SILSOL® silica technology introduces techniques that are easier to screen and work in combination with existing technologies to improve usage and stability, thereby reducing the time needed to scale up.
Grace’s SILSOL® silica active ingredient delivery technology is used with solvent impregnation to create amorphous solid dispersions. Due to our vast expertise in particle design, Grace can modify the pore size and surface characteristics of silica to accommodate various API molecules. The net result is enhanced bioavailability with improved stability.
Manufacturer |
GRACE |
---|---|
Quality |
JPE, USP-NF |
Cas-No |
7631-86-9 |
Einecs |
231-545-4 |
Composition |
mesoporous silica gel |
Dosage Form |
OSD |
Function |
DC Excipient, Drug Carrier |
Syloid 244FP€0.00 |
GRACE | Select options |
Syloid AL-1 FP€0.00 |
GRACE | Select options |